Dacomitinib is a small-molecule, irreversible inhibitor of HER1, HER2, and HER4, under development by Pfizer. Mutation or amplification of the HER gene is seen in several malignancies including lung, breast, gastric, head and neck, and colorectal cancers. This rise in HER levels disrupts normal cell control mechanisms, promoting the formation of aggressive tumor cells. Dacomitinib blocks the signaling in both wild-type and mutant epidermal growth factor receptor NSCLC, including forms which are resistant to reversible HER inhibitors.
4 Drug Overview
5 Product Profiles
5 dacomitinib : Non-small cell lung cancer (NSCLC)
LIST OF FIGURES
10 Figure 89: Datamonitor Healthcare’s drug assessment summary for cemiplimab in non-small cell lung cancer
12 Figure 92: Dacomitinib for non-small cell lung cancer – SWOT analysis
16 Figure 93: Datamonitor Healthcare’s drug assessment summary for dacomitinib in non-small cell lung cancer
LIST OF TABLES
6 Table 1: Dacomitinib drug profile
7 Table 2: Dacomitinib pivotal trial data in non-small cell lung cancer
8 Table 3: Dacomitinib Phase III trial data in non-small cell lung cancer
9 Table 4: Dacomitinib early-phase data in non-small cell lung cancer
11 Table 121: Cemiplimab patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
17 Table 6: Dacomitinib patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.